Spyre Therapeutics Files Material Definitive Agreement 8-K
Ticker: SYRE · Form: 8-K · Filed: Oct 15, 2025 · CIK: 1636282
| Field | Detail |
|---|---|
| Company | Spyre Therapeutics, Inc. (SYRE) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $18.50, $316.2 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, company-name-change
TL;DR
Spyre Therapeutics (formerly Aeglea) filed an 8-K for a material definitive agreement.
AI Summary
On October 13, 2025, Spyre Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The company, formerly known as Aeglea BioTherapeutics, Inc. until March 11, 2015, is incorporated in Delaware and headquartered in Waltham, MA.
Why It Matters
This filing indicates a significant new contract or partnership for Spyre Therapeutics, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, but the specifics are not detailed in this initial filing.
Key Numbers
- 001-37722 — SEC File Number (Identifies the company's filing with the SEC)
- 46-4312787 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Spyre Therapeutics, Inc. (company) — Registrant
- Aeglea BioTherapeutics, Inc. (company) — Former company name
- October 13, 2025 (date) — Date of earliest event reported
- 20150311 (date) — Date of name change
- Waltham, MA (location) — Principal executive offices location
FAQ
What is the nature of the material definitive agreement filed by Spyre Therapeutics?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 13, 2025.
What was Spyre Therapeutics' former company name?
Spyre Therapeutics, Inc. was formerly known as Aeglea BioTherapeutics, Inc.
Where are Spyre Therapeutics' principal executive offices located?
Spyre Therapeutics' principal executive offices are located at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453.
What is the SEC file number for Spyre Therapeutics?
The SEC file number for Spyre Therapeutics, Inc. is 001-37722.
Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 13.4 · Accepted 2025-10-15 16:02:23
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share SYRE The Nasdaq
- $18.50 — Stock"), at a public offering price of $18.50 per share. In addition, the Company gra
- $316.2 m — ny from the Offering were approximately $316.2 million, before deducting underwriting di
Filing Documents
- d40269d8k.htm (8-K) — 29KB
- d40269dex11.htm (EX-1.1) — 236KB
- d40269dex51.htm (EX-5.1) — 6KB
- g40269g1015075830714.jpg (GRAPHIC) — 2KB
- 0001193125-25-240237.txt ( ) — 456KB
- syre-20251013.xsd (EX-101.SCH) — 3KB
- syre-20251013_lab.xml (EX-101.LAB) — 18KB
- syre-20251013_pre.xml (EX-101.PRE) — 11KB
- d40269d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SPYRE THERAPEUTICS, INC. Date: October 15, 2025 By: /s/ Cameron Turtle Cameron Turtle Chief Executive Officer